Sorry, I don't understand your search. ×
Back to Search Start Over

Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009)

Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009)

Authors :
Andres Forero-Torres
Robert Wesolowski
Elizabeth Claire Dees
Nuzhat Pathan
Peter Kabos
Kristen J. Pierce
Rachelle Perea
Janice M. Lu
Kenneth A. Kern
HS Han
Aditya Bardia
Hope S. Rugo
Rachel M. Layman
Brett E. Houk
Source :
Journal of Clinical Oncology. 36:1040-1040
Publication Year :
2018
Publisher :
American Society of Clinical Oncology (ASCO), 2018.

Abstract

1040Background: The majority of women with ER+ MBC develop resistance to ET. ET plus a CDK4/6 inhibitor (CDKi 4/6) demonstrate improved progression-free survival (PFS) in first/later line MBC. Prec...

Details

ISSN :
15277755 and 0732183X
Volume :
36
Database :
OpenAIRE
Journal :
Journal of Clinical Oncology
Accession number :
edsair.doi...........e3797c91bd0848baa41ab2c8a3664369
Full Text :
https://doi.org/10.1200/jco.2018.36.15_suppl.1040